Business Standard

J&J, Astra explore modifying jabs in response to blood clot


Johnson & Johnson and Astrazenec­a are conducting early research into whether modificati­ons to their COVID-19 vaccines could eliminate or reduce the risk of rare blood clots linked to the shots, the Wall Street Journal reported, citing people close to the process. Astrazenec­a and J&J did not immediatel­y respond to Reuters' request for comment.

Newspapers in English

Newspapers from India